PubRank

Henk W Reesink

Author PubWeight™ 35.76‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004 7.79
2 Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum 2004 1.94
3 Vitamin D deficiency does not increase the risk of rheumatoid arthritis: comment on the article by Merlino et al. Arthritis Rheum 2006 1.79
4 Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology 2011 1.62
5 Antiviral effect of peginterferon alfa-2b and alfa-2a compared. J Hepatol 2006 1.42
6 Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 2005 1.38
7 Optimization of real-time PCR assay for rapid and sensitive detection of eubacterial 16S ribosomal DNA in platelet concentrates. J Clin Microbiol 2003 1.34
8 Transfusion-transmitted infectious diseases. Biologicals 2009 1.25
9 HTLV-I/II prevalence in different geographic locations. Transfus Med Rev 2004 1.14
10 Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection. J Infect Dis 2009 0.97
11 Detection of bacteria in platelet concentrates: comparison of broad-range real-time 16S rDNA polymerase chain reaction and automated culturing. Transfusion 2005 0.96
12 High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int 2007 0.95
13 Non-invasive evaluation of liver fibrosis: a comparison of ultrasound-based transient elastography and MR elastography in patients with viral hepatitis B and C. Eur Radiol 2013 0.94
14 Storage of platelets in additive solution for up to 12 days with maintenance of good in-vitro quality. Transfusion 2004 0.92
15 Viral kinetics of hepatitis C virus RNA in patients with chronic hepatitis C treated with 18 MU of interferon alpha daily. Eur J Gastroenterol Hepatol 2002 0.88
16 Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3.4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a. Scand J Gastroenterol 2008 0.87
17 Bone metabolism is altered in preclinical rheumatoid arthritis. Ann Rheum Dis 2010 0.87
18 Monocyte-derived dendritic cells from chronic HCV patients are not infected but show an immature phenotype and aberrant cytokine profile. Liver Int 2007 0.87
19 Multicenter performance evaluation of a transcription-mediated amplification assay for screening of human immunodeficiency virus-1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations. Transfusion 2005 0.87
20 Removal of contaminating DNA from commercial nucleic acid extraction kit reagents. J Microbiol Methods 2004 0.86
21 Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2014 0.85
22 Validation of the NucliSens Extractor combined with the AmpliScreen HIV version 1.5 and HCV version 2.0 test for application in NAT minipool screening. Transfusion 2002 0.84
23 Ultrasound evaluation of perihepatic lymph nodes during antiviral therapy with the protease inhibitor telaprevir (VX-950) in patients with chronic hepatitis C infection. Ultrasound Med Biol 2007 0.83
24 A European perspective on the management of donors and units testing positive for hepatitis B virus DNA. Transfusion 2006 0.81
25 Applications of real-time PCR in the screening of platelet concentrates for bacterial contamination. Expert Rev Mol Diagn 2006 0.78
26 Factor XIII Val34Leu mutation accelerates the development of fibrosis in patients with chronic hepatitis B and C. Hepatol Res 2012 0.77
27 Real-time amplification of HLA-DQA1 for counting residual white blood cells in filtered platelet concentrates. Transfusion 2004 0.76
28 Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients. Hepatology 2010 0.76
29 HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a. Scand J Gastroenterol 2011 0.75
30 Low-level HCV viraemia after initial response during antiviral therapy: transcription-mediated amplification predicts treatment failure. Antivir Ther 2007 0.75
31 [Reactivation of hepatitis B virus in patients with hematological neoplasms]. Ned Tijdschr Geneeskd 2009 0.75
32 Prediction of virologic response in difficult-to-treat chronic hepatitis C patients during high-dose interferon induction therapy. Scand J Gastroenterol 2008 0.75
33 Reply from the authors. Hepatol Res 2012 0.75